Stelios Papadopoulos and George Scangos reunite as Young leaves Biogen
This article was originally published in Scrip
Biogen Idec's chair William D Young is to retire from the company's board of directors – effective at the firm's 2014 annual meeting of stockholders. Mr Young has been a member of Biogen's board since 1997 and has served as chair for the last four years.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.